-

06:01:19 PM

ARDS Stock News

ARDS - Aridis Pharmaceuticals Inc

01/25/23 4:05 PM

Nasdaq : ARDS

clinical triallow float

Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301 with standard of care

RHEA-AI

neutral

01/17/23 4:30 PM

Nasdaq : ARDS

clinical triallow float

New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused on

RHEA-AI

neutral

12/28/22 8:30 AM

Nasdaq : ARDS

clinical triallow float

Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, will host a conference call and audio-only webcast on

RHEA-AI

neutral

12/12/22 8:05 AM

Nasdaq : ARDS

low float

(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing development of

RHEA-AI

very positive

12/12/22 7:00 AM

Nasdaq : ARDS

low float

Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing development of

RHEA-AI

very positive

12/05/22 7:00 AM

Nasdaq : ARDS

low float

Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a

RHEA-AI

positive

11/30/22 7:00 AM

Nasdaq : ARDS

clinical triallow float

Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced the closing of patient enrollment in

RHEA-AI

very positive

11/22/22 9:10 AM

Nasdaq : ARDS

conferenceslow float

Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company

RHEA-AI

neutral

10/04/22 8:00 AM

Nasdaq : ARDS

clinical triallow float

Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) announced today that patient enrollment is closed in the AR-301 Phase 3 clinical study. The

RHEA-AI

neutral

09/27/22 9:20 AM

Nasdaq : ARDS

offeringlow float

Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that due to adverse market conditions, it has

RHEA-AI

neutral

ARDS Data

IndustryResearch and Development in Biotechnology
Websitearidispharma.com
Security nameAridis Pharmaceuticals Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2834
Employees34
Tags
- Health Technology
- Pharmaceuticals: Major

About Aridis Pharmaceuticals Inc

Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary ?PEXTM and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality. The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients.